H. S. Rugo - Concepedia

Author

H. S. Rugo

University of California, San Francisco

Also Known As

D Berry, H Rugo, H S Rugo, H. Rugo, H. S. Rugo, H.S. Rugo, HopeS. Rugo, L Esserman, Laura Esserman

141

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Samsung Medical Center

About

H. S. Rugo is an author at University of California, San Francisco specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	28	843
2	Health Sciences	9	9	358
3	Immunology	7	7	215
4	Cell Biology	2	2	61
5	Nursing	1	1	14

H. S. Rugo

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Sylvia Adams, P. Schmid, H. S. Rugo, Annals of Oncology	2018	756
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy Matti Aapro, H. S. Rugo, Giada Rizzi, Annals of Oncology	2014	244
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J. O’Shaughnessy, Lee S. Schwartzberg, Michael Danso, Journal of Clinical Oncology	2011	244
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 H. S. Rugo, Sherene Loi, Sylvia Adams, Annals of Oncology Breast OncologyHealth SciencesMedicinePathologyPost-hoc Analysis	2019	113
LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Annals of Oncology Breast OncologyFinal Os AnalysisMedicinePharmacologyPathology	2020	61
A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia EJ Feldman, Karen Seiter, Lloyd E. Damon, Leukemia Hematological MalignancyElderly PatientsMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	1997	54
Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow Andrew Lin, Jeeyoung Park, Janet H. Scott, Journal of Clinical Oncology Breast OncologyDistant RecurrenceImmunologyTumor CellsMetronomic Chemotherapy	2008	53
The Role of Endoscopic Evaluation in Patients with Suspected Intestinal Graft-Versus-Host Disease After Allogeneic Bone-Marrow Transplantation Jonathan P. Terdiman, Claudia Linker, Curt A. Ries, Endoscopy	1996	46
A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab. Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Cancer Research Breast OncologyImmunologyPhase Ii StudyPharmacotherapyAbstract Abstract Withdrawn	2009	46
Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC) H. S. Rugo, Mario Campone, D. Amadori, Journal of Clinical Oncology First-line TherapyMetastatic Breast CancerBreast OncologyCancer TherapeuticsMedicine	2009	42

Page 1